NAD+ Energy Booster IV

REGEVITA's NAD+ Energy Booster infusion delivers nicotinamide adenine dinucleotide directly into the bloodstream — the only route that reliably raises NAD⁺ in tissues beyond what oral precursors (NMN, NR) can achieve at comparable cost. NAD⁺ is the central redox coenzyme in every living cell, shuttling electrons through the electron transport chain to generate ATP and serving as a substrate for sirtuins (longevity-associated deacetylases) and PARP enzymes involved in DNA repair. Cellular NAD⁺ concentrations decline by roughly 50% between young adulthood and age 60 — a drop linked to reduced mitochondrial efficiency, slower DNA repair, and impaired metabolic signalling. The infusion is administered under medical supervision at REGEVITA following a mandatory pre-treatment consultation.

The NAD+ Energy Booster at REGEVITA is the most clinically intensive infusion in the clinic's portfolio, reflecting both the potency of the molecule and the importance of careful titration during administration. Nicotinamide adenine dinucleotide is a dinucleotide coenzyme found in all living cells; it exists in two interconvertible forms — NAD⁺ (oxidised) and NADH (reduced) — that collectively drive cellular respiration, signal longevity pathways, and maintain genomic stability. The evidence base for IV NAD+ includes several mechanisms. As the primary electron carrier in oxidative phosphorylation, adequate NAD⁺ is required for efficient mitochondrial ATP production; declining NAD⁺ in ageing mitochondria reduces their energy output and increases reactive oxygen species leakage. NAD⁺ is also the obligate substrate for SIRT1–7 (the sirtuin family of class III HDACs), which regulate inflammation, fat metabolism, circadian rhythms, and stress resistance — and for PARP-1, which detects and initiates repair of single-strand DNA breaks. Without sufficient NAD⁺, PARP-1 stalls and breaks accumulate, accelerating genomic instability. At REGEVITA, the infusion is delivered slowly over 60–120 minutes (the rate-limiting step is patient tolerance — administering NAD⁺ too fast commonly causes a transient flushing sensation, chest tightness, or muscle cramping that resolves immediately when the drip is slowed). The medical team performs a pre-treatment consultation to review cardiovascular history and current medications, and adjusts the infusion speed to the individual patient's response during the first session. Primary indications include cognitive clarity and focus, mitochondrial energy restoration, alcohol and substance detoxification support, post-viral or chronic fatigue syndrome recovery, and as a cornerstone of comprehensive longevity programming. A course of 4–10 infusions is typically recommended; some patients schedule quarterly maintenance sessions thereafter. Doctor consultation is required before the first infusion.